Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency
about
Biologically-directed modeling reflects cytolytic clearance of SIV-infected cells in vivo in macaquesDendritic cells reveal a broad range of MHC class I epitopes for HIV-1 in persons with suppressed viral load on antiretroviral therapyRegulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART.A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.Utilizing the FIV model to understand dendritic cell dysfunction and the potential role of dendritic cell immunization in HIV infection.Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons.Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy.Dendritic cell-based human immunodeficiency virus vaccine.Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.CD8(+) T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjectsInterruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) and CD4(+) T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells.HIV-Specific CD8(+) T Lymphocytes in Blood of Long-Term HIV-Infected Hemophilia Patients.HIV-specific CD8⁺ T cells and HIV eradicationProfessional antigen presenting cells in human herpesvirus 8 infection.Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitopeEffective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T CellsProduction of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection.Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help?Programming T cell Killers for an HIV Cure: Teach the New Dogs New Tricks and Let the Sleeping Dogs LieRestoration of anti-human immunodeficiency virus type 1 (HIV-1) responses in CD8+ T cells from late-stage patients on prolonged antiretroviral therapy by stimulation in vitro with HIV-1 protein-loaded dendritic cellsParallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection.The impact of viral evolution and frequency of variant epitopes on primary and memory human immunodeficiency virus type 1-specific CD8⁺ T cell responses.Human immunodeficiency virus-type 1 specific cellular immunity in chronic infected patients on prolonged highly active antiretroviral treatment and on structured treatment interruption.Pediatric HIV-1-specific cytotoxic T-lymphocyte responses suggesting ongoing viral replication despite combination antiretroviral therapy.Large HIV-specific CD8 cytotoxic T-lymphocyte (CTL) clones reduce their overall size but maintain high frequencies of memory CTL following highly active antiretroviral therapy.CD8+ lymphocyte control of SIV infection during antiretroviral therapy
P2860
Q27319762-9A55B7BD-5BB2-4119-B9D0-B4122A422AA0Q28475576-6E8B2E52-C3EF-406A-8401-E399E0EB051EQ33547403-48F8DEA2-C4FE-499E-AAEF-74D89746DA23Q33603919-A8C631CC-3F48-4577-BBBB-AFC163002F76Q33653728-BE3EC057-9422-4990-960E-4755EB67F061Q33835126-535E8EC5-6D86-4255-A7FB-887FB8DA2F31Q33843388-E99BC61A-245D-4BEB-BAA7-DE7B6CE916F6Q33874652-3895ECB4-B2B5-4B8F-B675-210F0988379CQ33949316-900FB4A0-A8AF-4166-B0DF-69EC2D1C002FQ33998262-038CD4FF-51A4-42D2-BF32-0A14D3430164Q34159342-D8F9314E-B5E2-4B12-9910-A58CC0072DE5Q34326482-AD66AE17-39D3-4F96-A934-8980898A5B6EQ34332462-1A9A3B1C-CB94-4798-BD7F-601F808A6EA7Q35079104-ACA153E6-6093-487A-89CD-67773546726EQ36515071-33EE4B82-10DB-4340-AA73-F7A176327FE4Q36546999-E2147B07-AB97-4F24-828D-B86D51725FA6Q36627951-34A9369E-9A60-4D23-9AE8-E46B350E4869Q36974205-880D8A3C-E7FE-4851-AFBB-6B2D522B6285Q37099222-E420D094-D880-4D43-B9F7-6E14ECD39CF6Q38267445-BA6C6C74-608F-4EEF-9269-1802495C0638Q39201703-25E43367-3DE3-4F32-AA1A-CA476F32D60AQ39602544-7C3D11DE-7E44-4F5A-A7FC-0A6B20CABBEDQ41893684-0DA6A406-D651-4D94-9573-F7E12D2AA267Q41981778-568500EA-9009-434B-BD76-46FD40D41579Q45413163-078B8E5D-2D90-435C-B4B6-13873243BDB2Q46808721-0A5CC246-68F8-47FB-9897-A958A253A714Q47340952-32451BB9-1B5B-41D1-A39F-2EA6789353C9Q57281967-D598F5B6-9F79-485A-8B10-17CE254375B7
P2860
Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Anti-human immunodeficiency vi ...... with advanced immunodeficiency
@ast
Anti-human immunodeficiency vi ...... with advanced immunodeficiency
@en
type
label
Anti-human immunodeficiency vi ...... with advanced immunodeficiency
@ast
Anti-human immunodeficiency vi ...... with advanced immunodeficiency
@en
prefLabel
Anti-human immunodeficiency vi ...... with advanced immunodeficiency
@ast
Anti-human immunodeficiency vi ...... with advanced immunodeficiency
@en
P2093
P2860
P1433
P1476
Anti-human immunodeficiency vi ...... with advanced immunodeficiency
@en
P2093
C Kalinyak
C R Rinaldo
D K McMahon
J B Margolick
J W Mellors
L Borowski
S A Riddler
W H Hildebrand
P2860
P304
P356
10.1128/JVI.74.9.4127-4138.2000
P577
2000-05-01T00:00:00Z